General Information of Drug (ID: DMDKRS3)

Drug Name
Antistasin Drug Info
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDKRS3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting Coagulation factor Xa (F10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [3]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [4]
DU-176b DMCIJBH Atrial fibrillation BC81.3 Approved [5]
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [6]
BETRIXABAN DM2C4RF Venous thromboembolism BD72 Approved [7]
Lmw heparin DMJPD06 Coagulation defect 3B10.0 Approved [8]
Nadroparin calcium DMBNKST Coagulation defect 3B10.0 Approved [9]
Fondaparinux sodium DMWS3FH Deep vein thrombosis BD71 Approved [10]
Danaparoid DM6CLBN Deep venous clot BD71 Approved [11]
Coagulation Factor IX DM8HBJI Haemophilia B 3B11.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [2]

References

1 The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75.
2 Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
3 Pfizer. Product Development Pipeline. March 31 2009.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 Company report (Portola)
8 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
9 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
10 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
11 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
12 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.